VCEL Vericel Corporation

Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, and Gerard Michel, chief financial officer and vice president of corporate development, will present at the 27th Annual ROTH Conference at The Ritz-Carlton Hotel in Dana Point, California, on Wednesday, March 11, 2015, at 9:30am Pacific time.

The presentation will be webcast live and may be accessed from the events and presentations section of the Vericel website: http://investors.vcel.com/events.cfm.

About Vericel Corporation

Vericel Corporation (formerly Aastrom Biosciences, Inc.) is a leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. Vericel is also developing MACI™, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. For more information, please visit the company's website at www.vcel.com.

CONTACT: Chad Rubin
         The Trout Group
         crubin@troutgroup.com
         (646) 378-2947
         or
         Lee Stern
         The Trout Group
         lstern@troutgroup.com
         (646) 378-2922